Phytrol functional food products slated for late July test launch in two U.S. cities by Novartis/Quaker Oats joint venture Altus, Forbes reports July 3. Line of phytosterol-containing drinks, cereals and bars will be sold under Quaker Take Heart brand and be competitively priced with other specialty products. Revenue from Phytrol sales for fiscal Q3 (ended April 30) totaled approximately $232,000 (CAN$351,000), although majority of sales in preparation for test market launch were completed by February 2001, Forbes says. Phytrol sales for first nine months totaled about $1.3 mil. Vancouver-based firm reports Q3 net loss of roughly $2.2 mil., compared to $1.9 mil. loss in year-ago quarter. Company aims to launch CardioRex dietary supplement for cholesterol control in first half of 2002
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
